$TMCI
TREACE MEDICAL CONCEPTS, INC. Stock $tmci

$tmci Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024021228 Filed on February 27, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$51.11M	$62.21M	$187.1M
YoY Change	21.12%	25.0%	31.92%
Cost Of Revenue	$10.13M	$11.47M	$35.18M
YoY Change	25.97%	17.73%	27.82%
Gross Profit	$40.98M	$50.74M	$151.9M
YoY Change	19.98%	26.77%	32.91%
Gross Profit Margin	80.19%	81.56%	81.2%
Selling, General & Admin	$54.69M	$53.37M	$187.9M
YoY Change	22.84%	34.19%	38.61%
% of Gross Profit	133.45%	105.18%	123.69%
Research & Development	$5.259M	$4.152M	$15.44M
YoY Change	54.13%	10.75%	13.53%
% of Gross Profit	12.83%	8.18%	10.16%
Depreciation & Amortization	$1.909M	$1.769M	$5.352M
YoY Change	112.11%	92.91%	154.86%
% of Gross Profit	4.66%	3.49%	3.52%
Operating Expenses	$59.95M	$57.53M	$203.4M
YoY Change	25.07%	32.17%	36.34%
Operating Profit	-$18.97M	-$6.782M	-$51.43M
YoY Change	37.69%	93.94%	47.59%
Interest Expense	$1.317M	$405.0K	$5.167M
YoY Change	2.49%	-165.85%	17.49%
% of Operating Profit
Other Income/Expense, Net	$292.0K	$96.00K	$1.901M
YoY Change	-9.32%		-123.85%
Pretax Income	-$18.68M	-$6.281M	-$49.53M
YoY Change	38.81%	42.36%	15.68%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$18.68M	-$6.281M	-$49.53M
YoY Change	38.81%	42.36%	15.68%
Net Earnings / Revenue	-36.54%	-10.1%	-26.47%
Basic Earnings Per Share	-$0.30		-$0.81
Diluted Earnings Per Share	-$0.30	-$0.10	-$0.81
COMMON SHARES
Basic Shares Outstanding	61.76M	61.68M	60.85M
Diluted Shares Outstanding	61.79M		60.85M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$110.0M	$123.2M	$123.2M
YoY Change	-35.54%	51.62%	51.62%
Cash & Equivalents	$9.334M	$12.98M	$3.160M
Short-Term Investments	$100.7M	$110.2M	$110.2M
Other Short-Term Assets	$11.45M	$7.853M	$7.853M
YoY Change	149.57%	116.69%	116.69%
Inventory	$35.86M	$29.25M	$29.25M
Prepaid Expenses
Receivables	$30.08M	$38.06M	$38.06M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$187.4M	$198.4M	$198.4M
YoY Change	-16.02%	48.69%	48.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.52M	$22.30M	$31.56M
YoY Change	54.05%	45.38%	23.89%
Goodwill	$12.82M	$12.82M
YoY Change
Intangibles	$8.787M	$9.025M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$146.0K	$146.0K	$146.0K
YoY Change	-32.09%	0.0%	0.0%
Total Long-Term Assets	$55.33M	$53.55M	$53.55M
YoY Change	112.5%	108.99%	108.99%
TOTAL ASSETS
Total Short-Term Assets	$187.4M	$198.4M	$198.4M
Total Long-Term Assets	$55.33M	$53.55M	$53.55M
Total Assets	$242.7M	$251.9M	$251.9M
YoY Change	-2.59%	58.41%	58.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$21.15M	$11.84M	$11.84M
YoY Change	316.65%	36.54%	36.54%
Accrued Expenses	$15.16M	$10.46M	$30.17M
YoY Change	90.13%	68.24%	39.82%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$47.05M	$45.03M	$45.03M
YoY Change	101.96%	48.89%	48.89%
LONG-TERM LIABILITIES
Long-Term Debt	$53.08M	$53.01M	$53.01M
YoY Change	0.56%	0.56%	0.56%
Other Long-Term Liabilities	$37.00K	$37.00K	$15.93M
YoY Change	48.0%	-99.76%	2.5%
Total Long-Term Liabilities	$53.12M	$53.05M	$68.94M
YoY Change	0.59%	0.63%	1.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$47.05M	$45.03M	$45.03M
Total Long-Term Liabilities	$53.12M	$53.05M	$68.94M
Total Liabilities	$116.3M	$114.0M	$114.0M
YoY Change	27.07%	15.71%	15.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$152.9M	-$134.2M
YoY Change	55.73%	58.5%
Common Stock	$62.00K	$62.00K
YoY Change	1.64%	12.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$250.0K	$13.00K
YoY Change
Treasury Stock Shares
Shareholders Equity	$126.4M	$137.9M	$137.9M
YoY Change
Total Liabilities & Shareholders Equity	$242.7M	$251.9M	$251.9M
YoY Change	-2.59%	58.41%	58.41%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$18.68M	-$6.281M	-$49.53M
YoY Change	38.81%	42.36%	15.68%
Depreciation, Depletion And Amortization	$1.909M	$1.769M	$5.352M
YoY Change	112.11%	92.91%	154.86%
Cash From Operating Activities	-$7.221M	$532.0K	-$34.58M
YoY Change	-58.26%	-109.93%	12.99%
INVESTING ACTIVITIES
Capital Expenditures	$3.927M	$2.248M	$11.46M
YoY Change	165.7%	-3.6%	-22.78%
Acquisitions			$20.00M
YoY Change
Other Investing Activities	$7.685M	$7.255M	-$69.84M
YoY Change	-109.73%	-111.76%	13.23%
Cash From Investing Activities	$3.758M	$5.007M	-$81.30M
YoY Change	-104.67%	-107.82%	6.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net			$0.00
YoY Change
Cash From Financing Activities	-185.0K	165.0K	109.4M
YoY Change	-100.17%	-44.44%	425.73%
NET CHANGE
Cash From Operating Activities	-7.221M	532.0K	-34.58M
Cash From Investing Activities	3.758M	5.007M	-81.30M
Cash From Financing Activities	-185.0K	165.0K	109.4M
Net Change In Cash	-3.648M	5.704M	-6.491M
YoY Change	-135.98%	-108.26%	-92.48%
FREE CASH FLOW
Cash From Operating Activities	-$7.221M	$532.0K	-$34.58M
Capital Expenditures	$3.927M	$2.248M	$11.46M
Free Cash Flow	-$11.15M	-$1.716M	-$46.03M
YoY Change	-40.63%	-77.69%	1.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001630627
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	us-gaap	Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#InvestmentIncomeNet
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.treace.com/20231231#OperatingLeaseAndOtherLiabilities
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.treace.com/20231231#OperatingLeaseAndOtherLiabilities
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.treace.com/20231231#OperatingLeaseAndOtherLiabilities
CY2023	tmci	Elective Deferrals And Matching Contributions Eligibility Period ElectiveDeferralsAndMatchingContributionsEligibilityPeriod	P3M
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40355
CY2023	dei	Entity Registrant Name EntityRegistrantName	TREACE MEDICAL CONCEPTS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1052611
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Palmetto Park Place
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Ponte Vedra
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32081
CY2023	dei	City Area Code CityAreaCode	904
CY2023	dei	Local Phone Number LocalPhoneNumber	373-5940
CY2023	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
CY2023	dei	Trading Symbol TradingSymbol	TMCI
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	1223600000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	61755146
CY2023	dei	Auditor Firm AuditorFirmId	248
CY2023	dei	Auditor Name AuditorName	GRANT THORNTON LLP
CY2023	dei	Auditor Location AuditorLocation	Jacksonville, FL
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12982000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19473000
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	110216000
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	61779000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	980000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	735000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	38063000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	29196000
CY2023Q4	us-gaap	Inventory Net InventoryNet	29245000
CY2022Q4	us-gaap	Inventory Net InventoryNet	19330000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7853000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3624000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	198359000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	133402000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22298000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15338000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	475000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9025000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0
CY2023Q4	us-gaap	Goodwill Goodwill	12815000
CY2022Q4	us-gaap	Goodwill Goodwill	0
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9264000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10138000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	146000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	146000
CY2023Q4	us-gaap	Assets Assets	251907000
CY2022Q4	us-gaap	Assets Assets	159024000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11835000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8668000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10458000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6216000
CY2023Q4	tmci	Accrued Commissions AccruedCommissions	10759000
CY2022Q4	tmci	Accrued Commissions AccruedCommissions	7356000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7549000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7666000
CY2023Q4	tmci	Operating Lease And Other Liabilities OperatingLeaseAndOtherLiabilities	4432000
CY2022Q4	tmci	Operating Lease And Other Liabilities OperatingLeaseAndOtherLiabilities	339000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	45033000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	30245000
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	992000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1289000
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	53008000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	52711000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15891000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15539000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	37000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0
CY2023Q4	us-gaap	Liabilities Liabilities	113969000
CY2022Q4	us-gaap	Liabilities Liabilities	98495000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61749654
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61749654
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55628208
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55628208
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	62000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	55000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	271973000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	145221000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-134247000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-84720000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	163000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-27000
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1218
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	13000
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	137938000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	60529000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	251907000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	159024000
CY2023	us-gaap	Revenues Revenues	187118000
CY2022	us-gaap	Revenues Revenues	141838000
CY2021	us-gaap	Revenues Revenues	94419000
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	35181000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	25532000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49337000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42842000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20748000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.81
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.81
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.77
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.77
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.43
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.43
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60852153
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60852153
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	16888000
CY2023	us-gaap	Gross Profit GrossProfit	151937000
CY2022	us-gaap	Gross Profit GrossProfit	116306000
CY2021	us-gaap	Gross Profit GrossProfit	77531000
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	140894000
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	104567000
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	65405000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15440000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13584000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10204000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	47031000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	32999000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18432000
CY2023	us-gaap	Operating Expenses OperatingExpenses	203365000
CY2022	us-gaap	Operating Expenses OperatingExpenses	151150000
CY2021	us-gaap	Operating Expenses OperatingExpenses	94041000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-51428000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-34844000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-16510000
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	6726000
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	1313000
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	17000
CY2023	us-gaap	Interest Expense InterestExpense	5167000
CY2022	us-gaap	Interest Expense InterestExpense	4398000
CY2021	us-gaap	Interest Expense InterestExpense	4060000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4483000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2023	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	342000
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-403000
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1901000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7971000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4042000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-49527000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-42815000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20552000
CY2023	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0
CY2021	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	196000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-49527000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-42815000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20748000
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	190000
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-27000
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55276834
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55276834
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48415679
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48415679
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	776000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1830000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3409000
CY2021	tmci	Issuance Cost And Underwriting Discount IssuanceCostAndUnderwritingDiscount	10600000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	107610000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20552000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	93073000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2187000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	8111000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-42815000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-27000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	60529000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1869000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	17363000
CY2023	tmci	Issuance Cost And Underwriting Discount IssuanceCostAndUnderwritingDiscount	7500000
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	107527000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-49527000
CY2023	tmci	Unrealized Loss On Available For Sale Marketable Securities UnrealizedLossOnAvailableForSaleMarketableSecurities	190000
CY2023	tmci	Shares Directly Withheld From Employees For Tax Payment SharesDirectlyWithheldFromEmployeesForTaxPayment	-13000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	137938000
CY2023	us-gaap	Profit Loss ProfitLoss	-49527000
CY2022	us-gaap	Profit Loss ProfitLoss	-42815000
CY2021	us-gaap	Profit Loss ProfitLoss	-20552000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5352000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2133000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	685000
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	434000
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	411000
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	144000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	17352000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	8111000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	3409000
CY2023	tmci	Non Cash Lease Expense NonCashLeaseExpense	2461000
CY2022	tmci	Non Cash Lease Expense NonCashLeaseExpense	2522000
CY2021	tmci	Non Cash Lease Expense NonCashLeaseExpense	0
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	297000
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	244000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	176000
CY2023	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0
CY2022	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	173000
CY2021	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	72000
CY2023	tmci	Debt Extinguishment Loss DebtExtinguishmentLoss	0
CY2022	tmci	Debt Extinguishment Loss DebtExtinguishmentLoss	4483000
CY2021	tmci	Debt Extinguishment Loss DebtExtinguishmentLoss	0
CY2023	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	346000
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1406000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	126000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-205000
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-25000
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9301000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11039000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4226000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9848000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8769000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2741000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1210000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	668000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2417000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	146000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-119000
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	3076000
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3167000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4612000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1791000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	7528000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	7125000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6610000
CY2023	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-40000
CY2022	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	0
CY2021	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	0
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34575000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30648000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17193000
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	169865000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	63409000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	120024000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1729000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11458000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14838000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2705000
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	20000000
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-81299000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-76518000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2705000
CY2023	tmci	Proceeds From Interest Bearing Term Debt ProceedsFromInterestBearingTermDebt	0
CY2022	tmci	Proceeds From Interest Bearing Term Debt ProceedsFromInterestBearingTermDebt	49651000
CY2021	tmci	Proceeds From Interest Bearing Term Debt ProceedsFromInterestBearingTermDebt	0
CY2023	tmci	Proceeds From Interest Bearing Revolver Debt ProceedsFromInterestBearingRevolverDebt	0
CY2022	tmci	Proceeds From Interest Bearing Revolver Debt ProceedsFromInterestBearingRevolverDebt	3850000
CY2021	tmci	Proceeds From Interest Bearing Revolver Debt ProceedsFromInterestBearingRevolverDebt	0
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	989000
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2023	tmci	Payments On Interest Bearing Debt PaymentsOnInterestBearingDebt	0
CY2022	tmci	Payments On Interest Bearing Debt PaymentsOnInterestBearingDebt	33893000
CY2021	tmci	Payments On Interest Bearing Debt PaymentsOnInterestBearingDebt	0
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1788000
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	7500000
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	10600000
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	107527000
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	107610000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1869000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2187000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1830000
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	13000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	109383000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20806000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	107652000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6491000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-86360000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	87754000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19473000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	105833000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18079000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12982000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19473000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	105833000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	5167000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	4398000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	3900000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	15300000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2023	tmci	Right Of Use Asset Obtained In Exchange For Operating Lease Incentive RightOfUseAssetObtainedInExchangeForOperatingLeaseIncentive	-22000
CY2022	tmci	Right Of Use Asset Obtained In Exchange For Operating Lease Incentive RightOfUseAssetObtainedInExchangeForOperatingLeaseIncentive	3615000
CY2021	tmci	Right Of Use Asset Obtained In Exchange For Operating Lease Incentive RightOfUseAssetObtainedInExchangeForOperatingLeaseIncentive	0
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	190000
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-27000
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0
CY2023	tmci	Unsettled Matured Marketable Security Receivable From Broker UnsettledMaturedMarketableSecurityReceivableFromBroker	3000000
CY2022	tmci	Unsettled Matured Marketable Security Receivable From Broker UnsettledMaturedMarketableSecurityReceivableFromBroker	0
CY2021	tmci	Unsettled Matured Marketable Security Receivable From Broker UnsettledMaturedMarketableSecurityReceivableFromBroker	0
CY2023	tmci	Internally Developed Software Noncash Portion InternallyDevelopedSoftwareNoncashPortion	-11000
CY2022	tmci	Internally Developed Software Noncash Portion InternallyDevelopedSoftwareNoncashPortion	0
CY2021	tmci	Internally Developed Software Noncash Portion InternallyDevelopedSoftwareNoncashPortion	0
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1000
CY2023	tmci	Conversion Of Convertible Preferred Stock And Accrued Dividends On Convertible Preferred Stock Into Common Stock ConversionOfConvertiblePreferredStockAndAccruedDividendsOnConvertiblePreferredStockIntoCommonStock	0
CY2022	tmci	Conversion Of Convertible Preferred Stock And Accrued Dividends On Convertible Preferred Stock Into Common Stock ConversionOfConvertiblePreferredStockAndAccruedDividendsOnConvertiblePreferredStockIntoCommonStock	0
CY2021	tmci	Conversion Of Convertible Preferred Stock And Accrued Dividends On Convertible Preferred Stock Into Common Stock ConversionOfConvertiblePreferredStockAndAccruedDividendsOnConvertiblePreferredStockIntoCommonStock	7935000
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="formation_and_business" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Formation and Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the Company</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Company</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Treace Medical Concepts, LLC was formed on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">July 29, 2013</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, as a Florida limited liability company. Effective July 1, 2014, the entity converted to a Delaware corporation and changed its name to Treace Medical Concepts, Inc. (the "Company"). The Company is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. The Company received 510(k) clearance for the Lapiplasty System in March 2015 and began selling its surgical medical devices in September 2015. The Company has pioneered the proprietary Lapiplasty 3D Bunion Correction System – a combination of instruments, implants and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion. In addition, the Company offers advanced instrumentation and implants for use in other procedures performed in high frequency with bunion surgery. The Company operates from its corporate headquarters located in Ponte Vedra, Florida.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Initial Public Offering and Follow-on Offering</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 27, 2021, the Company completed its initial public offering ("IPO"). The Company received net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">107.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the IPO. O</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">n February 10, 2023, the Company completed a follow-on offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,476,190</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock, which included the exercise in full of the underwriters' option to purchase additional shares, at a price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The February 2023 offering resulted in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">107.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting underwriting discounts and commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and offering expenses payable by the Company of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p>
CY2023	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2013-07-29
CY2022	tmci	Surgical Instrument Expense SurgicalInstrumentExpense	2000000
CY2021	tmci	Surgical Instrument Expense SurgicalInstrumentExpense	900000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant estimates and assumptions include write-downs related to accounts receivable, reserves and inventories, valuation of intangible assets and goodwill, the recoverability of long-term assets, deferred tax assets and related valuation allowances, contingencies, earn-out liabilities, and stock-based compensation.</span></p>
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1000000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	700000
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	400000
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	400000
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	100000
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents, marketable securities, and accounts receivable. The Company maintains its cash with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation ("FDIC") insured limits. The Company's available-for-sale securities portfolio primarily consists of U.S. treasury and agency securities, money market funds, commercial paper, Yankee CDs, high credit quality asset-backed securities and corporate debt securities. The Company's investment policy requires its available for sale securities to meet certain criteria including investment type, credit ratings, and a maximum portfolio duration of one year.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company earns revenue from the sale of its products to customers such as hospitals and ambulatory surgery centers. The Company's accounts receivable is derived from revenue earned from customers. The Company performs ongoing credit evaluations of its customers' financial condition and generally requires no collateral from its customers. At December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, no customer accounted for more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of accounts receivable. For the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022, and 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were no customers that represented </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% or more of revenue.</span></p>
CY2023	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	200000
CY2023Q4	tmci	Revenue Recognition International Sales RevenueRecognitionInternationalSales	0
CY2023Q4	us-gaap	Contract With Customer Refund Liability ContractWithCustomerRefundLiability	0
CY2022Q4	us-gaap	Contract With Customer Refund Liability ContractWithCustomerRefundLiability	0
CY2021Q4	us-gaap	Contract With Customer Right To Recover Product ContractWithCustomerRightToRecoverProduct	0
CY2023	tmci	Revenue Recognition Shipments To Customers Right To Return Description RevenueRecognitionShipmentsToCustomersRightToReturnDescription	shipments to customers, the Company offers the right to return the product within 30 days for a full refund, and for returns between 30 and 90 days, the Company offers a full refund less a 15% restocking fee. The Company does not have a history of product returns for refund. Customer invoices are generally payable within 30 days. The Company's products are generally sold with a limited standard warranty to the original purchaser of the products against defects in workmanship and materials for 180 days. The Company's liability is limited to providing, at the Company's option, a full refund or credit of the purchase price, or repairing or replacing the product, provided that the customer returns the defective product within 180 days from the purchase date. To date, the Company has had negligible returns of any products alleged to be defective.
CY2023	us-gaap	Revenue Practical Expedient Incremental Cost Of Obtaining Contract RevenuePracticalExpedientIncrementalCostOfObtainingContract	true
CY2023	tmci	Shipping And Handling Costs ShippingAndHandlingCosts	1300000
CY2022	tmci	Shipping And Handling Costs ShippingAndHandlingCosts	800000
CY2021	tmci	Shipping And Handling Costs ShippingAndHandlingCosts	500000
CY2023	us-gaap	Advertising Expense AdvertisingExpense	16100000
CY2022	us-gaap	Advertising Expense AdvertisingExpense	15000000
CY2021	us-gaap	Advertising Expense AdvertisingExpense	13000000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023Q4	us-gaap	Product Liability Contingency Accrual Present Value ProductLiabilityContingencyAccrualPresentValue	0
CY2022Q4	us-gaap	Product Liability Contingency Accrual Present Value ProductLiabilityContingencyAccrualPresentValue	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49300000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42800000
CY2022	tmci	Depreciation And Amortization Expense On Physical Assets And Software DepreciationAndAmortizationExpenseOnPhysicalAssetsAndSoftware	2100000
CY2021	tmci	Depreciation And Amortization Expense On Physical Assets And Software DepreciationAndAmortizationExpenseOnPhysicalAssetsAndSoftware	700000
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1900000
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	0
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2023Q4	us-gaap	Cash Cash	9822000
CY2022Q4	us-gaap	Cash Cash	3262000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12982000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19473000
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	110053000
CY2023	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain	196000
CY2023	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	33000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	110216000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	61806000
CY2022	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain	79000
CY2022	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	106000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	61779000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	31046000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	19601000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8748000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4263000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22298000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15338000
CY2023	tmci	Depreciation And Amortization Expense On Physical Assets And Software DepreciationAndAmortizationExpenseOnPhysicalAssetsAndSoftware	4900000
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	300000
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	200000
CY2022	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	100000
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	2305000
CY2022Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	2299000
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	417000
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	412000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	424000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1727000
CY2023Q4	tmci	Accrued Compensation Expense AccruedCompensationExpense	3340000
CY2022Q4	tmci	Accrued Compensation Expense AccruedCompensationExpense	0
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3972000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1778000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10458000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6216000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1404000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	339000
CY2023Q4	tmci	Contingent Consideration ContingentConsideration	2977000
CY2022Q4	tmci	Contingent Consideration ContingentConsideration	0
CY2023Q4	us-gaap	Other Liabilities OtherLiabilities	51000
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	0
CY2023Q4	tmci	Operating Lease And Other Liabilities OperatingLeaseAndOtherLiabilities	4432000
CY2022Q4	tmci	Operating Lease And Other Liabilities OperatingLeaseAndOtherLiabilities	339000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	54000000
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	54000000
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	992000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1289000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	53008000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	52711000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	33333000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	20667000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	54000000
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	992000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	53008000
CY2022Q2	us-gaap	Line Of Credit Facility Borrowing Capacity Description LineOfCreditFacilityBorrowingCapacityDescription	The Company is required to either (i) maintain a minimum drawn balance under the revolving loan facility or (ii) pay a minimum balance fee that is equal to the amount of the minimum balance deficit multiplied by the applicable interest rate during the period. If the outstanding balance under the revolving loan facility exceeds the lesser of (i) 50% of the revolving borrowing capacity or (ii) 50% of the borrowing base, or the Company is in default, MidCap will apply funds collected from the Company's lockbox account to reduce the outstanding balance of the revolving loan facility ("Lockbox Deductions").
CY2022Q2	tmci	Revolving Borrowing Capacity Percentage RevolvingBorrowingCapacityPercentage	0.50
CY2022Q2	us-gaap	Line Of Credit Facility Interest Rate Description LineOfCreditFacilityInterestRateDescription	The loans bear interest at an annual rate based on a 30-day forward looking secured overnight financing rate plus 0.10% (subject to a floor of 1.0% and a cap of 3.0% for both loan agreements) plus (i) 6.0% under the term loan agreement and (ii) 4.0% under the revolving loan facility.
CY2022Q2	us-gaap	Line Of Credit Facility Frequency Of Payments LineOfCreditFacilityFrequencyOfPayments	Interest is payable monthly in arrears on the first day of each month and on the maturity of the loan agreements. The term loan agreement and the revolving loan facility are accruing interest as of December 31, 2023 at the capped interest rates of 9% and 7%, respectively. The Company is obligated to pay interest only for the first 48 months and straight-line amortization for the remaining 12 months, subject to the Company's election to extend the initial interest-only period by 12 months to 60 months total if the Company's trailing twelve-month revenue is at or above certain levels.
CY2022Q2	tmci	Debt Instrument Repayment Fee Percentage Year1 DebtInstrumentRepaymentFeePercentageYear1	0.03
CY2022Q2	tmci	Debt Instrument Repayment Fee Percentage Year3 DebtInstrumentRepaymentFeePercentageYear3	0.01
CY2022Q2	tmci	Debt Instrument Repayment Fee Percentage Final DebtInstrumentRepaymentFeePercentageFinal	0.03
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	300000
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	200000
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	200000
CY2023Q4	tmci	Accrued Liabilities Related To Litigation And Contingencies AccruedLiabilitiesRelatedToLitigationAndContingencies	0
CY2022Q4	tmci	Accrued Liabilities Related To Litigation And Contingencies AccruedLiabilitiesRelatedToLitigationAndContingencies	0
CY2023Q4	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P10Y
CY2023Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2000000
CY2023	tmci	Percentage Of Construction Cost Paid As Fees To Lessor PercentageOfConstructionCostPaidAsFeesToLessor	-0.015
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	700000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	200000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	0
CY2021	us-gaap	Payments For Rent PaymentsForRent	600000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	2400000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	2300000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	2200000
CY2023	tmci	Schedule Of Operating Lease Liability Balance Sheet Information Tabletextblock ScheduleOfOperatingLeaseLiabilityBalanceSheetInformationTabletextblock	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional information related to operating leases is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:65.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:74.985%;"></td> <td style="width:1.538%;"></td> <td style="width:1%;"></td> <td style="width:21.477%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average remaining lease term (years)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.2</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average discount rate</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.2</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> </tr> </table>
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y2M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.092
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2905000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1398000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3339000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3097000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3159000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	11839000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	25737000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8442000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	17295000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1404000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15891000
CY2023	us-gaap	Rental Income Nonoperating RentalIncomeNonoperating	300000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.01
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.05
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.08
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.03
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.01
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.06
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.01
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.01
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.01
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.25
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.26
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.32
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.02
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.04
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	22947000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15979000
CY2023Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	2618000
CY2022Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	1785000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3538000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1590000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	1092000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	1184000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2368000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1032000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1273000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	954000
CY2023Q4	tmci	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	4015000
CY2022Q4	tmci	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	3539000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1178000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	698000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	39029000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	26761000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35211000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22864000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3818000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3897000
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1573000
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1537000
CY2023Q4	us-gaap	Deferred Tax Liabilities Other Finite Lived Assets DeferredTaxLiabilitiesOtherFiniteLivedAssets	2217000
CY2022Q4	us-gaap	Deferred Tax Liabilities Other Finite Lived Assets DeferredTaxLiabilitiesOtherFiniteLivedAssets	2331000
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	28000
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	29000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3818000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3897000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35200000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22900000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	12300000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	10900000
CY2023	tmci	Operating Loss Carryforwards Expiration Year OperatingLossCarryforwardsExpirationYear	2034
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	14966893
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	13549282
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.3743
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.3761
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.3605
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.3708
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.3557
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.556
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0375
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0444
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0164
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0434
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0008
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0139
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7150755
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.57
CY2023	tmci	Share Based Compensation By Share Based Payment Arrangement Shares Available For Grant Granted ShareBasedCompensationByShareBasedPaymentArrangementSharesAvailableForGrantGranted	877910
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	23.67
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	495337
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.77
CY2023	tmci	Share Based Compensation By Share Based Payment Arrangement Shares Available For Grant Cancelled ShareBasedCompensationByShareBasedPaymentArrangementSharesAvailableForGrantCancelled	156311
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	17.33
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7377017
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y5M23D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.47
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	38409000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	7009511
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y4M20D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	6.03
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	38158000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4592722
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y5M23D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.65
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	35388000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17352000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8111000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3409000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.75
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.52
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.19
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	10100000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	5300000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	2000000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	13600000
CY2023	us-gaap	Description Of Defined Contribution Pension And Other Postretirement Plans DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans	Effective as of January 2021, the Company began sponsoring a 401(k) profit sharing plan trust for its employees who satisfy certain eligibility requirements. An employee will be eligible to become a participant in the plan for purposes of (i) elective deferrals and matching contributions after completing three consecutive months of service beginning on the employee's date of hire and (ii) employer profit sharing contributions after completing one year of service.
CY2023	tmci	Employer Profit Sharing Contributions Eligibility Service Period EmployerProfitSharingContributionsEligibilityServicePeriod	P1Y
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2023	tmci	Defined Contribution Plan Employees Matching Pre Tax Salary Contribution Percent DefinedContributionPlanEmployeesMatchingPreTaxSalaryContributionPercent	0.03
CY2023	tmci	Defined Contribution Plan Employees Matching Additional Contribution Percent DefinedContributionPlanEmployeesMatchingAdditionalContributionPercent	0.50
CY2023	tmci	Defined Contribution Plan Employees Pre Tax Salary Maximum Matching Contribution Percent DefinedContributionPlanEmployeesPreTaxSalaryMaximumMatchingContributionPercent	0.05
CY2023	tmci	Participants Vest Matching Contributions Period ParticipantsVestMatchingContributionsPeriod	P90D
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	1600000
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	1000000
CY2021	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	700000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-49527000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-42815000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20552000
CY2023	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0
CY2021	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	196000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-49527000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-42815000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20748000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60852153
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60852153
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55276834
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55276834
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48415679
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48415679
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.81
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.81
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.77
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.77
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.43
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.43
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8735137
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7745803

Files In Submission

Name	View Source	Status
0000950170-24-021228-index-headers.html	Edgar Link	pending
0000950170-24-021228-index.html	Edgar Link	pending
0000950170-24-021228.txt	Edgar Link	pending
0000950170-24-021228-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img234375980_0.jpg	Edgar Link	pending
img234375980_1.jpg	Edgar Link	pending
img234375980_10.jpg	Edgar Link	pending
img234375980_11.jpg	Edgar Link	pending
img234375980_12.jpg	Edgar Link	pending
img234375980_13.jpg	Edgar Link	pending
img234375980_14.jpg	Edgar Link	pending
img234375980_15.jpg	Edgar Link	pending
img234375980_16.jpg	Edgar Link	pending
img234375980_17.jpg	Edgar Link	pending
img234375980_18.jpg	Edgar Link	pending
img234375980_19.jpg	Edgar Link	pending
img234375980_2.jpg	Edgar Link	pending
img234375980_20.jpg	Edgar Link	pending
img234375980_21.jpg	Edgar Link	pending
img234375980_22.jpg	Edgar Link	pending
img234375980_3.gif	Edgar Link	pending
img234375980_4.jpg	Edgar Link	pending
img234375980_5.jpg	Edgar Link	pending
img234375980_6.jpg	Edgar Link	pending
img234375980_7.jpg	Edgar Link	pending
img234375980_8.jpg	Edgar Link	pending
img234375980_9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tmci-20231231.htm	Edgar Link	pending
tmci-20231231.xsd	Edgar Link	pending
tmci-ex10_14.htm	Edgar Link	pending
tmci-ex23_1.htm	Edgar Link	pending
tmci-ex31_1.htm	Edgar Link	pending
tmci-ex31_2.htm	Edgar Link	pending
tmci-ex32_1.htm	Edgar Link	pending
tmci-ex32_2.htm	Edgar Link	pending
tmci-ex97_1.htm	Edgar Link	pending
tmci-20231231_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TMCI
TREACE MEDICAL CONCEPTS, INC. Stock $tmci

2024 Q1 Form 10-K Financial Statement

#000095017024021228 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TMCI TREACE MEDICAL CONCEPTS, INC. Stock $tmci

2024 Q1 Form 10-K Financial Statement

#000095017024021228 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TMCI
TREACE MEDICAL CONCEPTS, INC. Stock $tmci